Clover Health (CLOV) Q2 Sales Up 34%
Clover Health Investments (NASDAQ:CLOV), a technology-focused Medicare Advantage insurer, reported its Q2 2025 results on August 5, 2025. The most notable news was robust revenue growth, with GAAP sales climbing to $477.6 million—surpassing analyst expectations of $468.3 million (GAAP). However, profitability metrics (GAAP and non-GAAP) weakened compared to Q2 2024. The company posted a net loss per share of $(0.02) (GAAP), GAAP EPS was a $(0.02) loss, swinging from a $0.01 profit in the previous year, and reported an insurance benefits expense ratio (BER) of 88.4% (non-GAAP). While revenue gains (GAAP) and Medicare Advantage membership growth were strong, rising medical costs significantly pressured margins, making this a mixed quarter overall.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Clover Health operates as a Medicare Advantage (MA) insurer, using technology to help doctors improve care for seniors. Its main offering is the Clover Assistant, a digital clinical support platform that provides data-driven recommendations to physicians. The company markets plans primarily in underserved regions, focusing on affordability and accessibility for Medicare-eligible individuals.
Source Fool.com
